C
Chaoyong Liu
Researcher at Beijing University of Chemical Technology
Publications - 53
Citations - 1891
Chaoyong Liu is an academic researcher from Beijing University of Chemical Technology. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 19, co-authored 39 publications receiving 1187 citations. Previous affiliations of Chaoyong Liu include Tianjin University & Peking University.
Papers
More filters
Journal ArticleDOI
Blood Exosomes Endowed with Magnetic and Targeting Properties for Cancer Therapy.
Hongzhao Qi,Chaoyong Liu,Lixia Long,Yu Ren,Shanshan Zhang,Xiaodan Chang,Xiaomin Qian,Huanhuan Jia,Jin Zhao,Jinjin Sun,Xin Hou,Xubo Yuan,Chunsheng Kang +12 more
TL;DR: A dual-functional exosome-based superparamagnetic nanoparticle cluster as a targeted drug delivery vehicle for cancer therapy and overcome major barriers to the utility of exosomes for cancer application are developed.
Journal ArticleDOI
Long non-coding RNA HOTAIR promotes glioblastoma cell cycle progression in an EZH2 dependent manner.
Kailiang Zhang,Xiaotian Sun,Xuan Zhou,Lei Han,Luyue Chen,Zhendong Shi,Anling Zhang,Minhua Ye,Qixue Wang,Chaoyong Liu,Jianwei Wei,Yu Ren,Jingxuan Yang,Jianning Zhang,Peiyu Pu,Min Li,Chunsheng Kang +16 more
TL;DR: It is found that EZH2 (predominant PRC2 complex component) inhibition blocked cell cycle progression in glioma cells, consistent with the effects elicited by HOTAIR siRNA.
Journal ArticleDOI
Star-branched amphiphilic PLA-b-PDMAEMA copolymers for co-delivery of miR-21 inhibitor and doxorubicin to treat glioma.
Xiaomin Qian,Lixia Long,Zhendong Shi,Chaoyong Liu,Mingzhe Qiu,Jing Sheng,Peiyu Pu,Xubo Yuan,Yu Ren,Chunsheng Kang +9 more
TL;DR: O amphiphilic star-branched copolymers are highly promising for their combinatorial delivery of genes and hydrophobic therapeutants and surprisingly exhibited an anti-proliferative efficiency compared with DOX or the miR-21i treatment alone.
Journal ArticleDOI
Multistage Delivery Nanoparticle Facilitates Efficient CRISPR/dCas9 Activation and Tumor Growth Suppression In Vivo
Qi Liu,Kai Zhao,Chun Wang,Zhanzhan Zhang,Chunxiong Zheng,Yu Zhao,Yadan Zheng,Chaoyong Liu,Yingli An,Linqi Shi,Chunsheng Kang,Yang Liu +11 more
TL;DR: The feasibility of utilizing MDNP to achieve tumor‐targeted delivery of CRISPR/dCas9 with sufficient levels to realize its therapeutic effects is suggested, suggesting the MNDP overcoming multiple physiological barriers and delivering the payload to tumor tissues with an optimal efficiency.
Journal ArticleDOI
Engineering blood exosomes for tumor-targeting efficient gene/chemo combination therapy.
Qi Zhan,Kaikai Yi,Hongzhao Qi,Sidi Li,Xueping Li,Qixue Wang,Yunfei Wang,Chaoyong Liu,Mingzhe Qiu,Xubo Yuan,Jin Zhao,Xin Hou,Chunsheng Kang +12 more
TL;DR: The potential of engineered blood exosomes as feasible co-delivery nanosystem for tumor-targeted and efficient combination therapy is demonstrated and is proved to be a general platform for the design of safe and effective combination therapy modality.